Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote

Risk committee has joined nearly all opioid reviews over past few years but didn’t for AcelRx's sublingual product; Raeford Brown, the analgesic advisory committee chair who was unable to attend the meeting, voices his displeasure with the vote. 

AcelRx Pharmaceuticals Inc.'s sublingual opioid Dsuvia (sufentanil) made waves by becoming the first opioid in 2018 to get a positive vote from a US FDA advisory committee. But Public Citizen is alleging that agency deliberately decided not to convene the full Drug Safety and Risk Management Advisory Committee (DSRMAC) to help deliver a positive vote.

In a letter dated Oct. 18 sent to FDA Commissioner Scott Gottlieb, Center for Drug Evaluation and Research (CDER)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers